Cell Cycle/Checkpoint
Cell cycle/checkpoint inhibitors are compounds that disrupt the normal progression of the cell cycle, particularly at key regulatory checkpoints. These inhibitors are crucial for studying cell division, understanding cancer cell proliferation, and developing anti-cancer therapies. By targeting specific phases of the cell cycle, these inhibitors can induce cell cycle arrest, leading to apoptosis or senescence in rapidly dividing cells. At CymitQuimica, we offer a diverse range of high-quality cell cycle/checkpoint inhibitors to support your research in cancer biology, cell biology, and drug development.
Subcategories of "Cell Cycle/Checkpoint"
- Aurora Kinase(112 products)
- CDK(541 products)
- Cell Cycle Arrest(5 products)
- Chk(47 products)
- DYRK(48 products)
- Dynamin(27 products)
- Ferroptosis(226 products)
- HSP(180 products)
- Integrin(240 products)
- Kinesin(88 products)
- LIM Kinase(20 products)
- Microtubule Associated(276 products)
- PKC(117 products)
- PLK(25 products)
- ROCK(63 products)
- Rho(5 products)
- Wee1(14 products)
- c-Myc(76 products)
Show 10 more subcategories
Found 3824 products of "Cell Cycle/Checkpoint"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK6-IN-1
CAS:CDK6-IN-1 (compound 4i) is an inhibitor of CDK6 that suppresses cell growth and induces cell cycle arrest at the G1 phase.Formula:C30H23N5Color and Shape:SolidMolecular weight:453.54CDK7-IN-31
CAS:CDK7-IN-31 (compound 13) is an effective and orally active inhibitor of cyclin-dependent kinase 7 (CDK7) with a dissociation constant (Kd) of 0.18 nM. This compound exhibits anticancer activity.Formula:C27H32F5N6O2PColor and Shape:SolidMolecular weight:598.55β-catenin-IN-8
CAS:β-catenin-IN-8 (Compound 25) is an inhibitor of β-catenin. It effectively lowers the levels of both β-catenin and c-Myc proteins and suppresses Wnt target genes (Fgf20 and Sall4). Additionally, β-catenin-IN-8 exhibits anticancer activity against colorectal cancer and possesses metabolic stability.Formula:C15H12ClN3O2SColor and Shape:SolidMolecular weight:333.79CDK1-IN-6
CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.Formula:C21H22N4OColor and Shape:SolidMolecular weight:346.43Plevitrexed
CAS:Plevitrexed, an oral TS inhibitor (Ki: 0.44 nM), targets α-folate receptor & reduced folate carrier, treats gastric cancer.Formula:C26H25FN8O4Purity:98%Color and Shape:SolidMolecular weight:532.53TMX-3013
CAS:TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.Formula:C17H14BrFN6O3SColor and Shape:SolidMolecular weight:481.3WEE1 degrader 1
WEE1degrader 1 (Compound 10) functions as a Wee1 degrader, exhibiting a DC50 value of 1.5 nM against Wee1. This compound also possesses anticancer properties that inhibit cell proliferation.Formula:C30H31N5O3Color and Shape:SolidMolecular weight:509.6RMS-07
CAS:RMS-07, a covalent MPS1/TTK inhibitor, has an IC50 of 13.1 nM, targeting a kinase hinge cysteine.Formula:C35H40N8O2Color and Shape:SolidMolecular weight:604.745-Iminodaunorubicin hydrochloride
CAS:5-Iminodaunorubicin HCl: quinone-modified anthracycline with antitumor properties, induces DNA breaks in cancer cells.Formula:C27H31ClN2O9Color and Shape:SolidMolecular weight:563.00RAD51-IN-8
RAD51-IN-8 inhibits RAD51-BRCA2 interaction and H4A4 with EC50 of 19 μM; a micromolar PPI inhibitor.Formula:C16H14Cl2FN3O2Color and Shape:SolidMolecular weight:370.21RAD51-IN-7
CAS:RAD51-IN-7 inhibits RAD51 gene, with potential for mitochondrial disorders. (From WO2021164746A1, cmpd 71)Formula:C25H31N5O4S2Color and Shape:SolidMolecular weight:529.67PD-L1-IN-7
CAS:PD-L1-IN-7 (compound CB31) serves as a PD-L1 inhibitor, effectuating PD-L1 internalization and retention within cells. It restrains the PD-1/PD-L1 interaction (IC 50: 0.2 nM), alters glycosylation patterns, and facilitates PD-L1 degradation. Additionally, PD-L1-IN-7 enhances T cell infiltration, boosts T cell function, and augments the capacity to destroy tumor cells.Formula:C46H50N6O7Color and Shape:SolidMolecular weight:798.93T-2513 hydrochloride
CAS:T-2513 hydrochloride: selective topoisomerase I inhibitor, binds DNA complex, halts DNA/RNA synthesis, causes cell death.Formula:C25H28ClN3O5Color and Shape:SolidMolecular weight:485.96GTSE1-IN-1
CAS:GTSE1-IN-1 (compound Y18), an orally active GTSE1 inhibitor, exhibits notable anticancer properties. It effectively represses the proliferation of cancer cells by downregulating GTSE1 transcription and expression, which leads to DNA damage and promotes persistent cell cycle arrest and cellular senescence. Moreover, GTSE1-IN-1 substantially reduces the adhesion, migration, and invasion of colorectal cancer HCT116 cells and non-small cell lung cancer A549 cells in vitro.Formula:C21H24FN7Color and Shape:SolidMolecular weight:393.46Pseudouridine 5'-OTBDPS
CAS:Pseudouridine5'-OTBDPS [5-(5-O-TBDPS-β-D-ribofuranosyl)uracil] is an intermediate of Pseudouridine.Formula:C25H30N2O6SiColor and Shape:SolidMolecular weight:482.60Dyrk1A-IN-2
Dyrk1A-IN-2 is a DYRK1A inhibitor (EC50: 37 nM). dyrk1A-IN-2 exhibits efficient promotion of human β-cell replication, as well as low cytotoxicity.Formula:C27H32N6O4Color and Shape:SolidMolecular weight:504.58Elacytarabine
CAS:Elacytarabine (M7594 0037), a lipid-conjugated derivative of the nucleoside analog cytarabine, is an antineoplastic drug. It has cytotoxicity in solid tumors.Formula:C27H45N3O6Purity:97.69%Color and Shape:SolidMolecular weight:507.66VCPIP1-IN-1
CAS:VCPIP1-IN-1 is a VCPIP1 inhibitor used in cancer research.Formula:C13H15ClN2O2Purity:99.3%Color and Shape:SolidMolecular weight:266.72Ref: TM-T88664
1mg49.00€5mg97.00€10mg154.00€25mg298.00€50mg472.00€100mg755.00€200mg1,017.00€1mL*10mM (DMSO)106.00€GFB-12811
CAS:GFB-12811 is an orally active, selective, and potent CDK5 inhibitor, used in the study of autosomal dominant polycystic kidney disease.Formula:C22H23F4N5OPurity:98.88%Color and Shape:SolidMolecular weight:449.44HRO761
CAS:HRO761 is a potent Werne r syndrome RecQ DNA deconjugase (WRN) inhibitor that can be used to study cancers such as colon and stomach cancer.Formula:C31H31ClF3N9O5Purity:98.74% - 99.62%Color and Shape:SolidMolecular weight:702.08Ref: TM-T72107
1mg57.00€5mg118.00€10mg167.00€25mg280.00€50mg475.00€100mg708.00€1mL*10mM (DMSO)778.00€
